This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Petri, A. Articles by Kauppinen, S. Search for Related Content PubMed PubMed Citation Articles by Petri, A. Articles by Kauppinen, S. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

MicroRNA Silencing in Primates: Towards Development of Novel Therapeutics

¹ Santaris Pharma, Kogle Allé 6, Hørsholm, Denmark and ² Wilhelm Johannsen Centre for Functional Genome Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark

Requests for reprints: Sakari Kauppinen, Santaris Pharma, Kogle Allé 6, DK-2970 Hørsholm, Denmark. Phone: 45-45179838; Fax: 45-45179898; E-mail: sk{at}santaris.com.

Key Words: antimiR • LNA • miRNA

MicroRNAs (miRNA) comprise an abundant class of small noncoding RNAs that act as important posttranscriptional regulators of gene expression. Accumulating evidence showing that aberrantly expressed miRNAs play important roles in human cancers underscores them as potential targets for therapeutic intervention. Recent reports on efficient miRNA silencing in rodents and nonhuman primates using high-affinity targeting by chemically modified antisense oligonucleotides highlight the utility of such compounds in the development of miRNA-based cancer therapeutics. [Cancer Res 2009;69(2):393–5]

This article has been cited by other articles:

				G. C. Prendergast Modeling Cancer Cell Signaling and Attacking It Cancer Reviews Online Content, February 1, 2009; 2009(2): 3 - 4. [Full Text] [PDF]